Solutions for Assay Automation to be Presented by Catalent Biologics at BEBPA US Bioassay Conference
SOMERSET, N.J. – February 19, 2019 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Michael Sadick, Ph.D., Principal Scientist, Catalent Biologics, will present at the annual US Bioassay Conference of the BioPharmaceutical Emerging Best Practices Association (BEBPA), taking place at the Crowne Plaza LA Harbor Hotel, San Pedro, California, on March 13-15, 2019.
On Friday, March 15 at 11 a.m., during the “Improving Your Bioassays” session, Dr. Sadick will discuss the challenges of assay automation, and their potential solutions in his presentation titled, “’I Can Let You Do That, Dave.’ Solutions for Automation of GMP Assays, Including Bioassays”. Dr. Sadick will talk through several strategies employed by Catalent, and will use case studies to demonstrate the benefits of assay automation and explain how challenges were overcome.
Dr. Sadick coordinates and oversees bioassay, ELISA and molecular biology projects for Catalent Biologics. Previously, he managed the company’s bioassay/relative potency team for 10 years at Catalent Biologics’ facility in Kansas City, Missouri. Prior to that, Dr. Sadick ran bioassay groups at Eli Lilly and Co. and Genentech. Dr. Sadick has an extensive background in cellular biology, cellular immunology and receptor signaling, molecular biology and biochemistry. He received his master’s degree and doctorate in immunology from the University of Washington in Seattle, and his bachelor’s degree in biology from Johns Hopkins University in Baltimore, Maryland.
To arrange a meeting with Dr. Sadick at the event, contact Richard Kerns at NEPR – email@example.com
+44 (0)7580 041073
+44 (0)161 728 5880
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.
More products. Better treatments. Reliably supplied.™